Statement of Changes in Beneficial Ownership (4)
November 04 2022 - 04:17PM
Edgar (US Regulatory)
|
FORM 4
[ ] Check this box if no longer subject to Section
16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL
OWNERSHIP OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
| 1. Name
and Address of Reporting Person * ALSTODT LANCE |
2. Issuer Name and Ticker or Trading
Symbol BioRestorative Therapies, Inc. [ BRTX ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)__X__
Director _____
10% Owner
__X__ Officer (give title
below) _____ Other
(specify below)
President, CEO, COB |
|
(Last)
(First)
(Middle)
C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE
1 |
3. Date of Earliest Transaction (MM/DD/YYYY)
11/3/2022
|
|
(Street)
MELVILLE, NY 11747
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or
Beneficially Owned
|
1.Title of Security
(Instr. 3) |
2. Trans. Date |
2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following
Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) |
7. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
Amount |
(A) or (D) |
Price |
|
Common Stock |
|
|
|
|
|
|
|
182921 (1) |
D |
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative
Security |
3. Trans. Date |
3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or
Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying
Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially
Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct
(D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr.
4) |
|
Code |
V |
(A) |
(D) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
|
Stock Option |
$13.5 |
11/3/2022 |
|
D |
|
|
293479 |
(2) |
3/18/2031 |
Common Stock |
293479 |
$0 (4) |
0 |
D |
|
|
Stock Option |
$5.08 |
11/3/2022 |
|
A |
|
293479 |
|
(2) |
3/18/2031 |
Common Stock |
293479 |
$0 (4) |
293479 |
D |
|
|
Stock Option |
$13.5 |
11/3/2022 |
|
D |
|
|
42059 |
(3) |
11/4/2031 |
Common Stock |
42059 |
$0 (4) |
0 |
D |
|
|
Stock Option |
$5.08 |
11/3/2022 |
|
A |
|
42059 |
|
(3) |
11/4/2031 |
Common Stock |
42059 |
$0 (4) |
42059 |
D |
|
| Explanation of
Responses: |
| (1) |
Includes 103,008 shares
received pursuant to an unvested restricted stock unit grant. Such
shares vest to the extent of 1,036 shares on November 18, 2022 and
January 18, 2023, 1,037 shares on December 18, 2022 and February
18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on
March 18, 2024. |
| (2) |
The option vests and becomes
exercisable to the extent of 146,740 shares on March 18, 2021,
36,684 shares on November 4, 2021 with the remaining 110,055 shares
in six nearly equal quarterly installments beginning December 18,
2021 and continuing every three months thereafter until fully
vested. |
| (3) |
The option vests and becomes
exercisable to the extent of 21,030 shares on November 4, 2021 with
the remaining 21,029 shares vesting quarterly in eight nearly equal
installments beginning on November 4, 2022. |
| (4) |
The reported transactions
involved an amendment of an outstanding stock option, resulting in
the deemed cancellation of the "old" stock option and the grant of
a "replacement" stock option with a reduced exercise
price. |
Reporting
Owners
|
|
Reporting Owner Name / Address |
Relationships
|
|
Director |
10% Owner |
Officer |
Other |
ALSTODT LANCE
C/O BIORESTORATIVE THERAPIES, INC.
40 MARCUS DRIVE, SUITE 1
MELVILLE, NY 11747 |
X |
|
President, CEO, COB |
|
Signatures
|
|
/s/ Lance Alstodt |
|
11/3/2022 |
| **Signature of Reporting
Person |
Date |
|
Reminder: Report on a separate line for each class
of securities beneficially owned directly or
indirectly. |
| * |
If the form is filed by more than one
reporting person, see Instruction 4(b)(v). |
| ** |
Intentional misstatements or omissions
of facts constitute Federal Criminal Violations. See 18
U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| Note: |
File three copies of this Form, one of
which must be manually signed. If space is insufficient, see
Instruction 6 for procedure. |
|
Persons who respond to the collection of information
contained in this form are not required to respond unless the form
displays a currently valid OMB control number. |
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Feb 2023 to Mar 2023
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Mar 2022 to Mar 2023
